Eric A. Hughes - 09 Aug 2024 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role: Executive Vice President, Global R&D and Chief Medical Officer
Signature: /s/ Dov Bergwerk as attorney-in-fact for Eric A. Hughes
Issuer symbol: TEVA
Transactions as of: 09 Aug 2024
Net transactions value: -$782,972
Form type: 4
Filing time: 13 Aug 2024, 16:02:28 UTC
Previous filing: 05 Aug 2024
Next filing: 13 Dec 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TEVA	Ordinary Shares	Sale	$782,972	-45,060	-100%	$17.38	0	09 Aug 2024	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.371 to $17.405, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Remarks:

Executive Vice President, Global R&D and Chief Medical Officer